子宫内膜癌分子分型的研究进展

苏远华; 肖雁冰

doi:10.11659/jjssx.08E023049

您当前的位置：

首页 >

文章列表页 >

子宫内膜癌分子分型的研究进展

综述 | 更新时间：2024-11-18

- 子宫内膜癌分子分型的研究进展
- Research progress on molecular typing of endometrial cancer
- 局解手术学杂志 2024年33卷第11期页码：1018-1022
- 作者机构：
  
  1.遵义医科大学研究生院，贵州遵义563000
  2.遵义医科大学附属妇幼保健院妇科，贵州遵义 563000
- 作者简介：
  
  肖雁冰，E-mail：273140954@qq.com
- 基金信息：
- DOI：10.11659/jjssx.08E023049
  中图分类号： R737.33
- 纸质出版日期：2024-11-25，
  
  收稿日期：2023-08-12，
- 稿件说明：
移动端阅览
苏远华,肖雁冰.子宫内膜癌分子分型的研究进展[J].局解手术学杂志,2024,33(11):1018-1022.

SU Yuan-hua,XIAO Yan-bing.Research progress on molecular typing of endometrial cancer[J].JOURNAL OF REGIONAL ANATOMY AND OPERATIVE SURGERY,2024,33(11):1018-1022.
苏远华,肖雁冰.子宫内膜癌分子分型的研究进展[J].局解手术学杂志,2024,33(11):1018-1022. DOI： 10.11659/jjssx.08E023049.

SU Yuan-hua,XIAO Yan-bing.Research progress on molecular typing of endometrial cancer[J].JOURNAL OF REGIONAL ANATOMY AND OPERATIVE SURGERY,2024,33(11):1018-1022. DOI： 10.11659/jjssx.08E023049.

摘要

子宫内膜癌（EC）为女性常见的盆腔恶性子宫肿瘤，其传统分类方法主要是按照组织病理学形态来分型，但这种分类方法具有较高的个人主观性、较低的重复性，且评估预后的价值有限。随着癌症分子机制的研究和基因测序技术的发展，现能够通过研究癌症基因组图谱（TCGA）来重新分类。这种新的分类方法可以帮助医生对EC患者进行更精准的风险评估，为其提供更有效的个性化治疗方案，还能利用TCGA数据预测EC患者的预后情况，有望改善EC患者的治疗结果和生存率。本文总结了国内外关于分子分型在EC中的相关研究进展，以期为临床上EC的诊治提供新的指导和思路。

Abstract

Endometrial cancer （EC） is a common pelvic malignant uterine tumor in women. The traditional classification method of EC is mainly based on histopathological morphology，while this classification method has high personal subjectivity，low repeatability，and limited value in assessing prognosis. With the research on the molecular mechanisms of cancer and the development of advanced gene sequencing technology， it is now possible to reclassify cancer by studying the cancer genome atlas （TCGA）. This new classification method can help doctors to conduct more accurate risk assessments， provide more effective personalized treatment plans for EC patients， and predict the prognosis of EC patients by using TCGA data， which is expected to improve the treatment outcomes and survival rates of EC patients. This paper summarized the related research on molecular typing in EC at home and abroad， in order to provide new guidance and ideas for the diagnosis and treatment of EC in clinical practice.

关键词

子宫内膜癌癌症基因组图谱分子分型ProMisE

Keywords

endometrial cancerthe cancer genome atlasmolecular typingProMisE

references

Sung H，Ferlay J，Siegel RL，et al.Global cancer statistics 2020：GLOBOCAN estimates of incidence and mortality world wide for 36 cancers in 185 countries［J］.CA Cancer J Clin，2021，71（3）：209-249.doi：10.3322/caac.21834http://dx.doi.org/10.3322/caac.21834.

Zheng R，Zhang S，Zeng H，et al.Cancer incidence and mortality in China，2016［J］.J Natl Cancer Cent，2022，2（1）：1-9.doi：10.1016/j.jncc.2022.02.002http://dx.doi.org/10.1016/j.jncc.2022.02.002.

Bokhman JV.Two pathogenetic types of endometrial carcinoma［J］.Gynecol Oncol，1983，15（1）：10-17.doi：10.1016/0090-8258（83）90111-7http://dx.doi.org/10.1016/0090-8258（83）90111-7.

Setiawan VW，Yang HP，Pike MC，et al.Type Ⅰ and Ⅱ endometrial cancers：have they different risk factors？［J］.J Clin Oncol，2013，31（20）：2607-2618.doi：10.1200/JCO.2012.48.2596http://dx.doi.org/10.1200/JCO.2012.48.2596.

Brinton LA，Felix AS，Mcmeekin DS，et al.Etiologic heterogeneity in endometrial cancer：evidence from a gynecologic oncology group trial［J］.Gynecol Oncol，2013，129（2）：277-284.doi：10.1016/j.ygyno. 2013.02.023http://dx.doi.org/10.1016/j.ygyno.2013.02.023.

Vermij L，Smit V，Nout R，et al.Incorporation of molecular characteristics into endometrial cancer management［J］.Histopathology，2020，76（1）：52-63.doi：10.1111/his.14015http://dx.doi.org/10.1111/his.14015.

Cancer Genome Atlas Research Network，Kandoth C，Schultz N，et al. Integrated genomic characterization of endometrial carcinoma［J］.Nature，2013，497（7447）：67-73.doi：10.1038/nature12113http://dx.doi.org/10.1038/nature12113.

National Comprehensive Cancer Network.NCCN clinical practice guidelines in oncology （NCCN guidelines）：uterine neoplasms．（1 Version.2020）［EB/OL］. ［2020-03-06］.https：//www.nccn.org/professionals/physician_gls/pdf/uterine.pdfhttps://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf.

Cree IA，White VA，Indave BI，et al.Revising the WHO classification：female genital tract tumors［J］.Histopathology，2020，76（1）：151-156.doi：10.1111/his.13977http://dx.doi.org/10.1111/his.13977.

Concin N，Creutzberg CL，Vergote I，et al.ESGO/ESTRO/ ESP guidelines for the management of patients with endometrial carcinoma［J］.Virchows Arch，2021，478（2）：153-190.doi：10.1136/ijgc-2020-002230http://dx.doi.org/10.1136/ijgc-2020-002230.

McConechy MK，Talhouk A，Li-Chang HH，et al.Detection of DNA mismatch repair （MMR） deficiencies by immunohistochemistry can effectively diagnose the microsatellite instability （MSI） phenotype in endometrial carcinomas［J］.Gynecol Oncol，2015，137（2）：306-310.doi：10.1016/j.ygyno.2015.01.541http://dx.doi.org/10.1016/j.ygyno.2015.01.541.

Ratovomanana T，Cohen R，Svrcek M，et al.Performance of next-generation sequencing for the detection of microsatellite instability in colorectal cancer with deficient DNA mismatch repair［J］.Gastroenterology，2021，161（3）：814-826.e7.doi：10.1053/j.gastro.2021.05.007http://dx.doi.org/10.1053/j.gastro.2021.05.007.

Raffone A，Travaglino A，Mascolo M，et al.TCGA molecular groups of endometrial cancer：pooled data about prognosis［J］.Gynecol Oncol，2019，155（2）：374-383.doi：10.1016/j.ygyno.2019.08.019http://dx.doi.org/10.1016/j.ygyno.2019.08.019.

Raffone A，Travaglino A，Gabrielli O，et al.Clinical features of ProMisE groups identify different phenotypes of patients with endometrial cancer［J］.Arch Gynecol Obstet，2021，303：1393-1400.doi：10.1007/s00404-021-06028-4http://dx.doi.org/10.1007/s00404-021-06028-4.

Brand RE，Dudley B，Karloski E，et al.Detection of DNA mismatch repair deficient crypts in random colonoscopic biopsies identifies Lynch syndrome patients［J］.Fam Cancer，2020，19（2）：169-175.doi：10.1007/s10689-020-00161-whttp://dx.doi.org/10.1007/s10689-020-00161-w.

Wethington Stephanie L，Fader Amanda N.ProMisE on the horizon：molecular classification of endometrial cancer in young women［J］.Gynecol Oncol，2019，153（3）：465-466.doi：10.1016/j.ygyno. 2019.05.001http://dx.doi.org/10.1016/j.ygyno.2019.05.001.

Talhouk A，Hoang LN，McConechy MK，et al.Molecular classification of endometrial carcinoma on diagnostic specimens is highly concordant with final hysterectomy：earlier prognostic information to guide treatment［J］.Gynecol Oncol，2016，143（1）：46-53.doi：10.1016/j.ygyno.2016.07.090http://dx.doi.org/10.1016/j.ygyno.2016.07.090.

Kommoss S，McConechy MK，Kommoss F，et al.Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series［J］.Ann Oncol，2018，29（5）：1180-1188.doi：10.1093/annonc/mdy058http://dx.doi.org/10.1093/annonc/mdy058.

Talhouk A，McConechy MK，Leung S，et al.Confirmation of ProMisE：a simple，genomics-based clinical classifier for endometrial cancer［J］.Cancer，2017，123（5）：802-813.doi：10.1002/cncr.30496http://dx.doi.org/10.1002/cncr.30496.

Raffone A，Travaglino A，Mascolo M，et al.Histopathological characterization of ProMisE molecular groups of endometrial cancer［J］.Gynecol Cncol，2020，157（1）：252-259.doi：10.1016/j.ygyno.2020.01.008http://dx.doi.org/10.1016/j.ygyno.2020.01.008.

Chung YS，Woo HY，Lee JY，et al.Mismatch repair status influences response to fertility-sparing treatment of endometrial cancer［J］.Am J Obstet Gynecol，2021，224（4）：370.e1-370.e13.doi：10.1016/j.ajog.2020.10.003http://dx.doi.org/10.1016/j.ajog.2020.10.003.

Raffone A，Catena U，Travaglino A， et al.Mismatch repair-deficiency specifically predicts recurrence of atypical endometrial hyperplasia and early endometrial carcinoma after conservative treatment：a multi-center study［J］.Gynecol Oncol，2021，161（3）：795-801.doi：10.1016/j.ygyno.2021.03.029http://dx.doi.org/10.1016/j.ygyno.2021.03.029.

Fader AN，Roque DM，Siegel E，et al.Randomized phase Ⅱ trial of carboplatin-paclitaxel compared with carboplatin-paclitaxel-trastuzumab in advanced （stage Ⅲ-Ⅳ） or recurrent uterine serous carcinomas that overexpress Her2/Neu （NCT01367002）：updated overall survival analysis［J］.Clin Cancer Res，2020，26（15）：3928-3935.doi：10.1158/1078-0432.CCR-20-0953http://dx.doi.org/10.1158/1078-0432.CCR-20-0953.

Makker V，Colombo N，Casado Herráez A，et al.Lenvatinib plus pembrolizumab for advanced endometrial cancer［J］.N Engl J Med，2022，386（5）：437-448.doi：10.1056/NEJMoa2108330http://dx.doi.org/10.1056/NEJMoa2108330.

Makker V，Taylorm H，Aghajanian C，et al.Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer［J］.J Clin Oncol，2020，38（26）：2981-2992.doi：10.1200/JCO.19.02627http://dx.doi.org/10.1200/JCO.19.02627.

Chen H，Liang M，Min J.Efficacy and safety of bevacizumab combined chemotherapy for advanced and recurrent endometrial cancer：a systematic review and meta-analysis［J］.Balkan Med J，2021，38（1）：7-12.doi：10.5152/balkanmedj.2021.20121http://dx.doi.org/10.5152/balkanmedj.2021.20121.

陈丽君，尹伶.新型靶向药物在HER2阳性乳腺癌脑转移中的作用［J］.局解手术学杂志，2022，31（5）：461-465.doi：10.11659/jjssx.10E021130http://dx.doi.org/10.11659/jjssx.10E021130.

Mamat Yusof MN，Chew KT，Kampan NC，et al.Expression of PD-1 and PD-L1 in endometrial cancer：molecular and clinical significance［J］.Int J Mol Sci，2023，24（20）：15233-15249.doi：10.3390/ijms242015233http://dx.doi.org/10.3390/ijms242015233.

Kir G，Olgun ZC，Soylemez T，et al.PD-L1 expression in mismatch repair-deficient endometrial carcinoma and tumor-associated immune cells：differences between MLH1 methylated and nonmethylated subgroups［J］.Int J Gynecol Pathol，2021，40（6）：575-586.doi：10.1097/PGP.0000000000000750http://dx.doi.org/10.1097/PGP.0000000000000750.

O'Malley DM，Bariani GM，Cassier PA，et al.Pembrolizumab in patients with microsatellite instability-high advanced endometrial cancer：results from the keynote-158 study［J］.J Clin Oncol，2022，40（7）：752-761.doi：10.1200/JCO.21.01874http://dx.doi.org/10.1200/JCO.21.01874.

Marabelle A，Fakih M，Lopez J，et al.Association of tumor mutational burden with outcomes in patients with advanced solid tumors treated with pembrolizumab：prospective biomarker analysis of the multicohort，open-label，phase 2 KEYNOTE-158 study［J］.Lancet Oncol，2020，21（10）：1353-1365.doi：10.1016/S1470-2045（20）30445-9http://dx.doi.org/10.1016/S1470-2045（20）30445-9.

Uppendahl L，Mullany SA，Winterhoff B.Molecular characterization of endometrial cancer and therapeutic implications［J］.Curr Opin Obstet Gynecol，2017，29（1）：35-39.doi：10.1097/GCO.0000000000000602http://dx.doi.org/10.1097/GCO.0000000000000602.

Keshinro A，Vanderbilt C，Kim JK，et al.Tumor-infiltrating lymphocytes，tumor mutational burden，and genetic alterations in microsatellite unstable，microsatellite stable，or mutant POLE/POLD1 colon cancer［J］.JCO Precis Oncol，2021，5：817-826.doi：10.1200/PO.20.00456http://dx.doi.org/10.1200/PO.20.00456.

Zhao S，Chen L，Zang Y，et al.Endometrial cancer in Lynch syndrome［J］.Int J Cancer，2022，150（1）：7-17.doi：10.1002/ijc.33763http://dx.doi.org/10.1002/ijc.33763.

Bucksch K，Zachariae S，Aretz S，et al.Cancer risks in Lynch syndrome，Lynch-like syndrome，and familial colorectal cancer type X：a prospective cohort study［J］.BMC Cancer，2020，20：1-11.doi：10.1186/s12885-020-06926-xhttp://dx.doi.org/10.1186/s12885-020-06926-x.

Pasanen A，Loukovaara M，Kaikkonen E，et al.Testing for Lynch syndrome in endometrial carcinoma：from universal to age-selective MLH1 methylation analysis［J］.Cancers，2022，14（5）：1348-1358.doi：10.3390/cancers14051348http://dx.doi.org/10.3390/cancers14051348.

Loukovaara M，Pasanen A，Bützow R.Mismatch repair protein and MLH1 methylation status as predictors of response to adjuvant therapy in endometrial cancer［J］.Cancer Med，2021，10（3）：1034-1042.doi：10.1002/cam4.3691http://dx.doi.org/10.1002/cam4.3691.

顾玉琴，华燕艳.21基因检测对ER阳性、淋巴结阴性乳腺癌患者术后复发转移的指导价值［J］.局解手术学杂志，2019，28（11）：906-909.doi：10.11659 /jjssx.07E018024http://dx.doi.org/10.11659/jjssx.07E018024.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

MDC1和MMR蛋白在子宫内膜癌中的表达及临床意义